On July 1, 2021 PDX Pharmaceuticals reported that in collaboration with OHSU, has received a perfect score on its fast track SBIR grant application to the NCI. The application focuses on development of ARACTM pipeline. Grant title: Novel Nano-immunotherapy for Treatment of Non-small Cell Lung Cancer, requested budget of $2.26 M over 3 years.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Furthermore, the team scored very high (18) on its direct phase II SBIR grant application to the NCI. The application focuses on IND enabling studies of AIRISETM pipeline. Grant title: In Situ Tumor Vaccination with a Nano-oligo Therapeutic to Induce Whole-body Antitumor Immune Response, requested budget of $2.15 M over 1.5 years .

The current NCI-SBIR payline is 22 and below. Therefore, we anticipate both applications will be awarded (pending council review).

ARACTM stands for Antigen Release Agent and Checkpoint Inhibitor

AIRISETM stands for Augmenting Immune Responses and Inhibiting the Suppressive Environment of Tumors